11,12-Epoxy-5,8,14-eicosatrienoic acid | 81276-02-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 11,12-Epoxy-5,8,14-eicosatrienoic acid
• 英文别名: (5E,8E)-10-[3-[(E)-oct-2-enyl]oxiran-2-yl]deca-5,8-dienoic acid
• CAS: 81276-02-0
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.5
• InChiKey: DXOYQVHGIODESM-ATELOPIESA-N

物化性质

• 闪点：
  9 °C
• 碰撞截面：
  184.4 Ų [M-H]-; 186.7 Ų [M+Na]+

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  F,Xi
• 危险类别码：
  R36/37/38,R11
• 危险品运输编号：
  UN 1170 3/PG 3
• 安全说明：
  S16,S26,S36

文献信息

• Means and methods for treating peripheral and cardiovascular diseases via modulation of arteriogenesis
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2030631A1

  公开（公告）日：2009-03-04

  The present invention relates to a pharmaceutical composition comprising (a) a polynucleotide comprising or consisting of a nucleotide sequence encoding a polypeptide with the amino acid sequence as set forth in SEQ ID NO: 2; (b) a polynucleotide comprising or consisting of a nucleotide sequence which is a fragment of a nucleotide sequence encoding the polypeptide with the amino acid sequence as set forth in SEQ ID NO: 2, wherein the polypeptide encoded by said polynucleotide has arteriogenic activity; (c) a polynucleotide comprising or consisting of a nucleotide sequence encoding a polypeptide, wherein said polypeptide exhibits at least 70% sequence identity with the sequence of the polypeptide encoded by the polynucleotide of (a) or (b) over the entire length, and wherein said polypeptide has arteriogenic activity; and/or (d) a polypeptide encoded by the polynucleotide of any one of (a) to (c).

  本发明涉及一种药物组合物，其包含(a)多核苷酸，该多核苷酸包含或由编码具有 SEQ ID NO: 2 所述氨基酸序列的多肽的核苷酸序列组成；(b)多核苷酸，该多核苷酸包含或由核苷酸序列组成，该核苷酸序列是编码具有 SEQ ID NO：2 所列氨基酸序列的核苷酸序列片段，其中所述多核苷酸编码的多肽具有动脉生成活性；(c) 包含或由编码多肽的核苷酸序列组成的多核苷酸，其中所述多肽与(a)或(b)的多核苷酸编码的多肽序列在整个长度上至少有 70% 的序列同一性，且所述多肽具有动脉生成活性；和/或 (d) (a)至(c)中任一项的多核苷酸编码的多肽。
• METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US20150246075A1

  公开（公告）日：2015-09-03

  Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.
• US9056085B2
  申请人：——

  公开号：US9056085B2

  公开（公告）日：2015-06-16